1. Program Coordinator: Laura Kasman, Ph.D. [email_address] 2. M&I program currently 17 Ph.D. students 4 MD/Ph.D. students 1 DMD/Ph.D. student 2 Masters students 15 Departmental…

1. WELCOME TO EUFETS GMBHYour Provider ofIntegrated Product Development Services for Cell & Gene TherapyEUFETS GmbH - A Company of BioNTech AG 2. EUFETS is part of BioNTech…

4 Biological Products: Manufacturing, Handling, Packaging and Storage Nahla S. Barakat King Saud University, College of Pharmacy, Dept. of Pharmaceutics, Saudi Arabia 1.…

Slide 1 16 th Annual NIH SBIR/STTR Conference Functional Down-to-Earth Advice for understanding the FDA Chris Sasiela, PhD, RAC NHLBI Office of Translational Alliances and…

Slide 1 FDA Oversight of Cell Therapy Clinical Trials Celia Witten, Ph.D., M.D. Office Director, Office of Cellular, Tissue, and Gene Therapies CBER/FDA ISSCR/CIRM/ISCT Workshop…

Slide 1 European Parliament Advanced Therapies Hearing May 11, 2006 Advanced Therapies The proposed EU regulation from the viewpoint of a Pharmaceutical company with experience…

OCTGT Guidance Document Update Rachael Anatol, Ph.D. Associate Director for Policy-New Legislation February 26, 2014 Outline Good Guidance Practices Guidance basics Guidances…

Mitochondrial Manipulation Technology in Assisted Reproduction For the Prevention of Transmission of Mitochondrial Disease or Treatment of Infertility Deborah Hursh, Ph.D.…

Innovation Through Collaboration: Why the CSS Working Groups are Important to the FDA Steve Wilson, DrPH, CAPT USPHS Director, FDA/CDER/OTS/OB/DBIII 2014 Computational Science…

The FDA Review Process Dan Takefman, PhD Chief, Gene Therapy Branch DCGT/OCTGT/CBER/FDA IOM Meeting 6/4/13 Overview IND Review Process Regulatory framework Discipline review…